1. BRAF V600E mutations in patients with papillary thyroid cancer is associated with an increase in mortality.
2. Despite an association, BRAF V600E does not appear to add prognostic information after adjusting for clinical and histopathological features of the tumor.
Study Rundown: While this retrospective study observed a significant association between the BRAF V600E mutation and papillary thyroid cancer (PTC) associated mortality, statistical significance was not maintained after adjusting for clinical and histopathologic features of an aggressive tumor. The stipulated interaction between the mutation and clinicopathological factors suggests that the mutation may play a role in driving the molecular pathogenesis which leads to aggressive tumor behavior. Given that BRAF V600E testing does not seem to add more prognostic information for patients, it does not currently appear provide any utility in everyday clinical practice in the management of PTC.
In-Depth [retrospective, multicenter study]: This study collected patient data from 1,849 individuals with PTC treated and followed in 13 medical centers situated in 7 countries from 1978 to 2011. The overall prevalence of BRAF V600E mutation was 45.7% with an overall mortality of 3% (56/1849), 80.4% (45/56) of which were positive for BRAF V600E. Deaths per 1000 person-years was 12.87 vs. 2.52 in BRAF V600E vs. mutation negative patients with an HR of 2.66 (95% CI, 1.30-5.43). When aggressive features of the tumor (e.g. distant metastasis) were included for analysis, the association was no longer significant (HR 1.21; 95% CI, 0.53-2.76). It is notable that some of the clinicopathological factors (e.g. age, lymph node status) showed an additive interaction with the BRAF V600E mutation, significantly increasing mortality risk.
By Elizabeth Park and Rif Rahman
More from this author: Trigger exposure in migraine patients results in migraine with aura only in a small subset of patients, Choosing a prenatal diagnostic test: Microarray analysis shown equal to karyotyping, STEMO unit delivery of tpa reduces call to needle time in acute stroke patients, High-dose multivitamin supplements do not decrease disease progression or death in HIV patients receiving HAART ,Pediatric patients not receiving quality palliative care despite agreement between parents and caregivers on valued elements of care ,Combined BRAF and MEK inhibition in metastatic melanoma significantly improves progression free survival
© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. Content is produced in accordance with fair use copyrights solely and strictly for the purpose of teaching, news and criticism.